retatrutide phase 2 nejm 2023 weight loss percent 48 weeks 🚨 Today, retatrutide, the GIP/GLP-1/glucagon triple agonist, just delivered TRIUMPH-2 top-line results. A study in those with concurrent obesity and type diabetes. 📊 Mean body change at 80 weeks: ⬇️ Semaglutide and Cardiovascular Outcomes in

Pregnant and breastfeeding women are generally advised against using Semaglutide, as its safety during pregnancy has not been established

They are also the number one reason people botch the tirzepatide to retatrutide transition

Body composition changes show large fat mass reductions but also measurable lean mass loss that scales with total weight lost

Moreover, retatrutides ability to slow down gastric emptying results in a prolonged feeling of satisfaction after meals, further aiding weight loss efforts

Atypical antipsychotics can cause dramatic weight gain and increase diabetes risk

But if its been more than 5 days since your missed dose, skip the missed dose and go back to your regular dosing schedule